Replies to post #126342 on Biotech Values

[BTH]

According to Mitch Gold, today he said:

As of August 31, the company had cash, cash equivalents, and short and long term investments of approximately $600 million dollars. Given the current cash balance and the reduced levels of spending following the restructuring, Dendreon expects to have sufficient cash to enable the company to achieve a cash flow break even position in the United States at an annual run rate of approximately $500 million in revenue

I don't know when his timeline for that run-rate is? This year? Next year? 2021?

BTW, what I find laughable, is that when the stock was at $1, Aschoff and Pantginis both had STRONG SELLS on DNDN. When the stock went to $20, they upgrade to BUY. How's that going for them?

[oc631]

Geoffrey Porges of Sanford Bernstein says Provenge will achieve peak annual sales of $450M in 2021, allowing DNDN to reach marginal profitability ten years from now

Only some younger members on this board might remember what Provenge was 10 years from now.